Phase IV AI-BRIDGE Trial: Point-of-Care Diabetic Retinopathy Screening vs Standard Care — Addressing Health Equity in Primary Care

References

1. 1.Campbell, M. K., Piaggio, G., Elbourne, D. R., & Altman, D. G. (2012). Consort 2010 statement: extension to cluster randomised trials. BMJ, 345, e5661. https://doi.org/10.1136/bmj.e5661
2. 2.Lundeen, E. A., Burke-Conte, Z., Rein, D. B., Wittenborn, J. S., Saaddine, J., Lee, A. Y., & Flaxman, A. D. (2019). Prevalence of diabetic retinopathy in the US in 2021. JAMA Ophthalmology, 137(11), 1233-1240. https://doi.org/10.1001/jamaophthalmol.2019.4993
3. 3.Mansberger, S. L., Gleitsmann, K., Gardiner, S., Sheppler, C., Demirel, S., Wooten, K., & Becker, T. (2013). Comparing the effectiveness of telemedicine and traditional surveillance in providing diabetic retinopathy screening examinations. Archives of Ophthalmology, 131(9), 1143-1150. https://doi.org/10.1001/archophthalmol.2013.1424
4. 4.Teo, Z. L., Tham, Y. C., Yu, M., Chee, M. L., Rim, T. H., Cheung, N., ... & Wong, T. Y. (2021). Global prevalence of diabetic retinopathy and projection of burden through 2045. Ophthalmology, 128(11), 1580-1591. https://doi.org/10.1016/j.ophtha.2021.04.027
5. 5.University of Wisconsin, Madison. (2024). Multicenter National Parallel Cluster Randomized Controlled Superiority Trial Comparing an Artificial Intelligence-Based Screening Strategy to Usual Care for Improving Eye-Care Follow-Up Among Patients With Diabetes (AI-BRIDGE Trial). ClinicalTrials.gov. NCT06763952. https://clinicaltrials.gov/study/NCT06763952
6. 6.Zhang, X., Saaddine, J. B., Chou, C. F., Cotch, M. F., Cheng, Y. J., Geiss, L. S., ... & Klein, R. (2010). Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA, 304(6), 649-656. https://doi.org/10.1001/jama.2010.1111